Skip to content

VINORELBINE INHIBITS ONCOGENIC FUNCTIONS OF MKK3: A NEW THERAPEUTIC OPPORTUNITY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519459-27-00
Acronym
VIMAC
Enrollment
25
Registered
2025-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

METASTATIC COLORECTAL CANCER

Brief summary

ORR is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator-reported measurements. Responses will be evaluated with a chest and abdominal computed tomography (CT) scan every 8 weeks. Patients who do not have an on-study assessment will be included in the analysis as non-responders.

Detailed description

Progression-free survival (PFS).Overall survival (OS).Toxicity rate.Quality of Life (QoL) is

Interventions

DRUGVINORELBINE
DRUGVinorelbine 30 mg soft capsules

Sponsors

I.F.O. Istituti Fisioterapici Ospitalieri
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
ORR is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator-reported measurements. Responses will be evaluated with a chest and abdominal computed tomography (CT) scan every 8 weeks. Patients who do not have an on-study assessment will be included in the analysis as non-responders.

Secondary

MeasureTime frame
Progression-free survival (PFS).Overall survival (OS).Toxicity rate.Quality of Life (QoL) is

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026